Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
siG12D-LODER + folfirinox
- Development stage
- Unknown
- Lead developer
- Silexion Therapeutics
- Modality
- Small Molecules, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intratumoral (siG12D-LODER), Intravenous (folfirinox)
01
Overview
**siG12D-LODER + folfirinox** is a combination therapy consisting of siG12D-LODER, a miniature biodegradable polymeric implant delivering a small interfering RNA (siRNA) targeting the KRAS G12D mutation, and FOLFIRINOX, a multi-agent chemotherapy regimen (folinic acid, fluorouracil, irinotecan, and oxaliplatin). siG12D-LODER is implanted directly into the tumor where it slowly releases siG12D siRNA, effectively silencing mutant KRAS mRNA expression and inhibiting tumor growth. Combined with FOLFIRINOX, this regimen is under clinical investigation as a targeted first-line treatment for locally advanced, unresectable pancreatic cancer. The siRNA therapy is designed for local, sustained delivery to overcome systemic delivery barriers, displaying anti-tumor, anti-metastatic, and anti-proliferative activity.
- Other names
- siG12D-LODER + folfirinox
02
Targets
TS (Thymidylate synthase)TOP1 (DNA Topoisomerase I)DNAKRASG12V (KRAS G12V)
Beyond the preview
Go deeper on siG12D-LODER + folfirinox.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on siG12D-LODER + folfirinox.